Gilead and Merck Report Positive Phase 3 HIV Treatment Results

Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, combining islatravir and lenacapavir, successfully met its primary efficacy endpoints.

The Product

The islatravir/lenacapavir combination is the first oral HIV treatment administered once weekly, potentially reducing dosing frequency from daily to weekly. Islatravir (Merck) is a reverse transcriptase inhibitor, while lenacapavir (Gilead) is a capsid inhibitor.

Pricing and Availability

Pricing details and regulatory submission timelines have not been announced. The companies plan to submit full data to regulatory authorities for approval.

Competition

This treatment competes with existing daily oral therapies like Gilead's Biktarvy and ViiV Healthcare's Triumeq, as well as long-acting injectables like Cabenuva. If approved, it would be the first once-weekly oral option.

Potential Impact on Stocks

For Gilead, this could strengthen its HIV portfolio, which already includes Biktarvy. For Merck, it represents a strong entry into the HIV market. Positive results support stock outlook, but commercial success depends on pricing and regulatory approval.